File Download

There are no files associated with this item.

Supplementary

Conference Paper: Garadacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial

TitleGaradacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial
Authors
Li, Philip Hei
Issue Date20-Jul-2023
Persistent Identifierhttp://hdl.handle.net/10722/336572

 

DC FieldValueLanguage
dc.contributor.authorLi, Philip Hei-
dc.date.accessioned2024-02-16T10:31:44Z-
dc.date.available2024-02-16T10:31:44Z-
dc.date.issued2023-07-20-
dc.identifier.urihttp://hdl.handle.net/10722/336572-
dc.languageeng-
dc.relation.ispartofUS HAEA National Summit (20/07/2023-23/07/2023, , , Florida)-
dc.titleGaradacimab for hereditary angioedema prophylaxis: long term efficacy and safety from the Phase 3 VANGUARD trial and first interim analysis of the open-label extension trial-
dc.typeConference_Paper-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats